Obesity Surgery

, Volume 22, Issue 7, pp 1060–1067 | Cite as

Remission of Insulin Resistance in Type 2 Diabetic Patients After Gastric Bypass Surgery or Exenatide Therapy

  • Wang Yong
  • Wei Shibo
  • Liu JingangEmail author
Clinical Research



Gastric bypass surgery and exenatide therapy represent two relatively new methods in treating morbid obesity and type 2 diabetes, although there are many differences between them. With the data supported from our hospital, we just want to investigate the differences between bypass surgery and exenatide injection and want to answer the question: Which one is the best? And Why?


Data from January 2009 to January 2010 were summarized for comparison at Shengjing hospital, including weight loss, plasma glucose and insulin changes, glycosylated hemoglobin, and the subjective scores of patients themselves. Plasma lipoprotein and serum ions were measured to evaluate the nutrition status.


Patients in the GB group received more weight loss and better glucose control compared with the EX group. At 6 months, feeding insulin level in the GB group was 18.1 ± 3.2 mU/L, which was much lower than that in the EX group (64.5 ± 13.2 mU/L, P < 0.01). The Hb1AC level in the GR group was 6.08 ± 0.56 %, much lower than that in the EX group (7.19 ± 0.72 %, P < 0.01). We did not find any statistical differences in lipoprotein, plasma ions, and subjective scores between the GB and EX groups.


Gastric bypass surgery is better in weight control and in the remission of insulin resistance compared with exenatide therapy. Both methods were safe and have no nutritional disorder in early stage, although the transferring in the GB group was higher than the EX group. The subjective scores from both groups declared that both methods could be accepted by patients.


Gastric bypass surgery Type 2 diabetes mellitus Exenatide 



All authors thank Zhang Yan for her kind help in revising this paper.

Sources of Funding

The paper was supported by grants from “Outstanding Scientific Fund of Shengjing Hospital” to Wang Y., “National Nature Science Funding of China (81000158 to Wang Y.), and Educational Funding of Liaoning (L2010591 to Wang Y.).

Conflict of Interest

All authors, including Yong Wang, Shibo Wei, and Jingang Liu, had no conflict of interest in this paper.


  1. 1.
    Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding. Ann Surg. 2010;252:966–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhang H, Wang Y, Zhang J, et al. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol. 2011;31:2063–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–69.PubMedCrossRefGoogle Scholar
  6. 6.
    Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord. 2004;28:963–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.PubMedCrossRefGoogle Scholar
  8. 8.
    Chelikani PK, Shah IH, Taqi E, et al. Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats. Obes Surg. 2010;20:1281–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375:408–18.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee W-J, Chong K, Chen C-Y, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index <35 kg/m2. Obes Surg. 2011;21:889–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.PubMedCrossRefGoogle Scholar
  14. 14.
    Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84. discussion 484-65.PubMedGoogle Scholar
  15. 15.
    Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237:751–6. discussion 757-8.PubMedGoogle Scholar
  16. 16.
    Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Morinigo R, Lacy AM, Casamitjana R, et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg. 2006;16:1594–601.PubMedCrossRefGoogle Scholar
  18. 18.
    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Barnett A. Exenatide. Expert Opin Pharmacother. 2007;8:2593–608.PubMedCrossRefGoogle Scholar
  20. 20.
    Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11:191–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of General Surgery, Shengjing HospitalChina Medical UniversityShenyangChina

Personalised recommendations